**Specifications Table**TableSubject areaBiology, BiochemistryMore specific subject areaPlasma markers; Tissue FibrosisType of dataTables; FiguresHow data was acquiredELISAData formatAnalyzedExperimental\
factorsMeasurement of PCPE-1 concentrations in human plasma using sandwich ELISAExperimental\
featuresA procedure for determination of human PCPE-1 concentrations by ELISA was developed using a specific monoclonal antibody for immobilization of human PCPE-1 and a polyclonal rabbit antibody against human PCPE-1 for its detection. PCPE-1 concentrations in plasma samples from healthy individuals and liver fibrosis patients were determined using this assay.Data source locationTel Aviv University, Tel Aviv, IsraelData accessibilityData is provided within this article

**Value of data**•An ELISA method for determination of procollagen C-proteinase enhancer 1 (PCPE-1) concentrations in human plasma is described.•The method can be used for determination of PCPE-1 concentrations in other body fluids.•The data highlights the potential of PCPE-1 as a new non-invasive biomarker of liver fibrosis, which could be valuable clinically.

1. Data {#s0005}
=======

The data includes two Figures and three Tables. [Fig. 1](#f0005){ref-type="fig"} presents a calibration curve for determination of human PCPE-1 concentrations. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} provide the plasma concentrations of PCPE-1 in healthy individuals and liver fibrosis patients, respectively. [Table 3](#t0015){ref-type="table"} summarizes the clinical features of the patients. [Fig. 2](#f0010){ref-type="fig"} compares the average plasma concentrations of PCPE-1 in healthy individuals and liver fibrosis patients. [Supplemental Tables S1 and S2](#s0055){ref-type="sec"} provide raw data used to calculate the inter- and intra-assay coefficients of variability, respectively.Fig. 1Standard curve for quantification of huPCPE-1 by sandwich ELISA. Increasing amounts of purified recombinant huPCPE-1 were adsorbed to wells pre-coated with a mouse monoclonal antibody to huPCPE-1. Bound PCPE-1 was detected using a rabbit polyclonal antibody to huPCPE-1 and quantified using an APA-conjugated goat anti rabbit IgG antibody. Each value represents mean±standard deviation (SD); *n*=2. mOD, Optical Density at 405 nm expressed in milli units.Fig. 1Fig. 2PCPE-1 plasma concentrations in healthy (control) subjects and liver fibrosis patients. Data from [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} (presented as the mean±standard deviation; *n*=5).Fig. 2Table 1Plasma concentrations of PCPE-1 in healthy (control) individuals.Table 1IndividualGenderAgePCPE-1 plasma concentration\
(ng/ml±SD)C1F31312.7±16.5C2F56339.2±14.4C3M52317.8±35.1C4M28285.5±51.1C5M35329.1±44.4Mean±SD316.9±20.3[a](#tbl1fna){ref-type="table-fn"}[^2]Table 2Plasma concentrations of PCPE-1 in liver fibrosis patients.Table 2PatientGenderAgePCPE-1 plasma concentration\
(ng/ml±SD)P1F59342.3±26.9P2F42618.5±32.1P3M56433.3±24.7P4M54299.9±31.0P5M64546.8±30.1Mean±SD448.1±134.3[^3]Table 3Etiology, clinical features and MELD indexes of liver fibrosis patients.Table 3PatientCauseComplicationsAdditional disordersMELDP1HBVGastropathy, Controlled ascitesHypertension, Obesity, Ovary cancer2P2HBVEsophageal varicesNone4P3HCVBleeding varicesDiabetes Mellitus Type 25P4HBVBleeding varices, Controlled ascites, EncephalopathyDiabetes Mellitus Type 212P5HCVNoneHypothyroidism9[^4]

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Proteins and antibodies {#s0015}
----------------------------

Human recombinant PCPE-1 (huPCPE-1) was produced in 293-EBNA cells and purified from conditioned culture media as described [@bib1], [@bib2]. Monoclonal antibody 7A11/1 to huPCPE-1 was produced in our laboratory and is available commercially (Sigma, Santa Cruz). Rabbit polyclonal antibody to human recombinant PCPE-1 was prepared in our laboratory and its IgG fraction isolated from the serum using standard protocols. Similar polyclonal antibodies are available commercially (AssayPro, Proteintech etc.) and can be used instead. Alkaline phosphatase (APA) conjugated goat antibody to rabbit IgG, a monoclonal antibody against the Flag peptide (M2), and bovine serum albumin (RIA grade; cat \# A7888) were from Sigma.

2.2. Experimental design {#s0020}
------------------------

Experiments were approved by the Sheba Medical Center ethics committee (SMC-9650-12). Five liver cirrhosis patients at ages 42--64 years old and five healthy individuals at ages 28--56 years old were randomly selected. All of the participating individuals provided written informed consent.

2.3. Preparation of plasma samples {#s0025}
----------------------------------

Blood was drown into plastic Citrate tubes (BD). After one to two hours at room temperature, the tubes were centrifuged (2000*g*; 15 min; room temperature) and plasma was transferred into Eppendorf tubes. Plasma samples were divided into aliquots and stored at −80 °C until use, avoiding repeated thawing and freezing.

2.4. Sandwich ELISA {#s0030}
-------------------

The ELISA for human PCPE-1 was conducted as previously described [@bib3] with the following modifications: (1) samples contained either known amounts of huPCPE-1 [@bib1] ([Fig. 1](#f0005){ref-type="fig"}) or human plasma samples diluted in 5% BSA in PBS (blocking buffer); (2) wells were coated with monoclonal antibody 7A11/1 (5 μg/ml) to capture the antigen; (3) bound huPCPE-1 was detected using rabbit polyclonal antibody to huPCPE-1 (IgG fraction; 0.1 μg/ml); (4) APA-conjugated goat antibody to rabbit IgG (1:2,000) served for quantification of huPCPE-1. As a control, wells were coated with equivalent amounts of monoclonal antibody M2 (vs. the Flag peptide; instead of antibody 7A11/1), in which case, absorbance was identical to that of the blanks (uncoated wells or wells to which no PCPE-1 was added) namely, no PCPE-1 binding was evident.

2.5. Statistical analysis {#s0035}
-------------------------

Statistical significance was evaluated using two-tailed independent *t*-test. *P* value \<0.05 was considered statistically significant.
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[^1]: Current address: Clinical Biochemistry and Pharmacology Laboratory , Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel.

[^2]: This value is practically identical to the previously reported [@bib4] value of 305 ng/ml (median; obtained by Western blotting of human sera samples and quantification of PCPE-1 band intensity), supporting the validity of our ELISA. C, control (healthy); F, female; M, male; Age is expressed in years. *n*=8 (two dilutions, each measured in duplicates on two different days).

[^3]: P, patient; F, female; M, male; Age is expressed in years. *n*=4 (two dilutions each measured in duplicates).

[^4]: P, patient; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, Model for End-stage Liver Disease (a measure of mortality risk in patients with end-stage liver disease; <http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease>).
